<DOC>
	<DOCNO>NCT00479401</DOCNO>
	<brief_summary>The objective trial conduct early Parkinson 's Disease ( PD ) patient determine efficacy ( measure change baseline end maintenance phase total score Unified Parkinson 's Disease Rating Scale ( UPDRS ) Parts II III combine ) , safety , tolerability Pramipexole Extended Release ( ER ) ( daily dose 0.375mg 4.5mg q.d . ) comparison placebo , test non-inferiority two formulation ( ER IR ) pramipexole . In addition , efficacy Pramipexole Immediate Release ( IR ) compare placebo , assay sensitivity</brief_summary>
	<brief_title>Efficacy , Safety , Tolerability Pramipexol ER Versus Pramipexol IR Versus Placebo Early PD Patients</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<criteria>1 . Male female patient idiopathic Parkinsons disease ( PD ) confirm least two follow sign : rest tremor , bradykinesia , rigidity . 2 . Parkinsons disease diagnose within 5 year . 3 . Patients 30 year age old time diagnosis . 4 . Modified Hoehn Yahr stage 1 3 . 5 . Patients require additional therapy/ introduction therapy ( de novo patient ) treat parkinsonian symptom time enrollment ( screen visit , V1 ) accord investigator judgement . 1 . Atypical parkinsonian syndrome due drug ( e.g. , metoclopramide , flunarizine ) , metabolic disorder ( e.g. , Wilson 's disease ) , encephalitis degenerative disease ( e.g. , progressive supranuclear palsy ) . 2 . Dementia , define MiniMental State Exam score &lt; 24 screen visit 3 . Any psychiatric disorder accord Diagnostic Statistical Manual Mental Disorders 4th ( DSMIV ) 4 . History psychosis 5 . Clinically significant electrocardiogram ( ECG ) abnormalities screen visit 6 . Clinically significant hypotension 7 . Malignant melanoma history previously treat malignant melanoma 8 . Any clinically significant disease , whether treat , could put patient risk could prevent compliance completion study 9 . Pregnancy 10 . Sexually active female childbearing potential use medically approve method birth control 11 . Serum level Aspartate Aminotransferase ( AST ) , Alanine Aminotransferase ( ALT ) , alkaline phosphatase bilirubin &gt; 2 Upper Limit Normal ( ULN ) 12 . Patients creatinine clearance &lt; 50 mL/min 13 . Any dopamine agonist ( include pramipexole ) within 4 week prior baseline visit , LDopa within 8 week prior baseline visit . 14 . Total cumulative duration prior exposure Levodopa 3 month . 15 . Any medication ( include intramuscular formulation ) central dopaminergic antagonist activity within 4 week prior baseline visit 16 . Any following drug within 4 week prior baseline visit : methylphenidate , cinnarizine , amphetamine . 17 . Flunarizine within 3 month prior baseline visit 18 . Known hypersensitivity Pramipexole excipients 19 . Drug abuse ( include alcohol ) , accord Investigators judgement , within 2 year prior screen . 20 . Participation investigational drug study use investigational drug within one month five time halflife investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>